Axitinib in combination with pembrolizumab in patients (pts) with advanced renal cell carcinoma (aRCC): Preliminary safety and efficacy results von Atkins, M.B., Plimack, E.R., Puzanov, I., Fishman, M.N., McDermott, D., Cho, D.C., Vaishampayan, U., George, S., Olencki, T., Tarazi, J., Rosbrook, B., Fernandez, K., Keefe, S., Choueiri, T.

Volltext

83P Evaluation of concordance between PD-L1 immunohistochemistry 28-8 and 22C3 pharmDx assays in metastatic urothelial carcinoma (mUC) in PIVOT-10 von Siefker-Radtke, A.O., Hoch, U., Loriot, Y., Balar, A.V., Bilen, M.A., Tannir, N.M., Cho, D.C., Choudhury, A., Chien, D., Yu, D., Currie, S.L., Novotny, J., Santiago, L., Tagliaferri, M.A., Zalevsky, J., Huddart, R.A.

Volltext

Prospective validation of prognostic scores to improve patient selection for immuno-oncology trials von Massard, C, Segal, N H, Cho, D C, Papadimitrakopoulou, V A, Rizvi, N A, Cho, B C, Yu, L, Yang, H, Hsieh, H-J, Zhang, J, Zhao, W, Gao, G, Guo, X, Abdullah, S, Englert, J, Soria, J-C, Dar, M, Roskos, L, Ferte, C, Antonia, S J

Volltext

Updated efficacy and safety data of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated anaplastic thyroid cancer (ATC) von Keam, B., Kreitman, R.J., Wainberg, Z.A., Cabanillas, M.E., Cho, D.C., Italiano, A., Stein, A., Cho, J.Y., Schellens, J.H.M., Wen, P.Y., Zielinski, C.C., Boran, A.D., Mookerjee, B., Burgess, P., Rangwala, F., Subbiah, V.

Volltext

127TiP PROPEL: A phase I/II trial of bempegaldesleukin (NKTR-214) in combination with pembrolizumab (pembro) in patients (pts) with advanced solid tumours von Reck, M., Cappuzzo, F., Rodriguez-Abreu, D., Cho, D.C., Schwarz, J.K., Riese, M.J., Gupta, A., Chan, T., Saab, R., Singel, S., Lin, W., Tagliaferri, M., Spigel, D.R.

Volltext

666P Pembrolizumab (pembro) monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC): Results after a minimum of 41 months of follow-up from KEYNOTE-42... von McDermott, D.F., Lee, J-L., Bjarnason, G.A., Larkin, J., Gafanov, R., Kochenderfer, M.D., Jensen, N.V., Donskov, F., Malik, J., Poprach, A., Tykodi, S.S., Alonso-Gordoa, T., Cho, D.C., Geertsen, P.F., Climent Duran, M.A., Di Simone, C., Liu, H., Burgents, J., Rodriguez-Lopez, K., Atkins, M.B.

Volltext

Preliminary results of PROCLAIM-CX-072: The first-in-human, dose-finding trial of PD-L1 probody therapeutic CX-072 as monotherapy in patients (pts) with advanced solid tumors von Boni, V, Garcia-Corbacho, J, Ott, P A, Cho, D C, Autio, K A, Uboha, N, Spira, A I, Humphrey, R, Will, M, Naing, A, Thistlethwaite, F, de Vries, E G E, Arkenau, H-T

Volltext

First in human study with GSK3359609 [GSK609], inducible T cell co-stimulator (ICOS) receptor agonist in patients [Pts] with advanced, solid tumors: Preliminary results from INDUCE... von Hansen, A., Bauer, T.M., Moreno, V., Maio, M., Groenland, S., Martin-Liberal, J., Gan, H., Rischin, D., Millward, M., Olszanski, A.J., Cho, D.C., Paul, E., Ballas, M., Ellis, C., Zhou, H., Yadavilli, S., Sadik Shaik, J., Schmidt, E.V., Hoos, A., Angevin, E.

Volltext

1119PD - Inducible T cell costimulatory (ICOS) receptor agonist, GSK3359609 (GSK609) alone and in combination with pembrolizumab (pembro): Preliminary results from INDUCE-1 expansi... von Rischin, D., Groenland, S.L., Lim, A.M.L., Martin-Liberal, J., Moreno, V., Trigo Perez, J.M., Le Tourneau, C., Mathew, M., Cho, D.C., Hansen, A.R., Vincente-Baz, D., Maio, M., Italiano, A., Bauman, J.R., Chisamore, M., Zhou, H., Ellis, C., Ballas, M., Hoos, A., Angevin, E.

Volltext

Inducible T cell costimulatory (ICOS) receptor agonist, GSK3359609 (GSK609) alone and in combination with pembrolizumab (pembro): Preliminary results from INDUCE-1 expansion cohort... von Rischin, D., Groenland, S.L., Lim, A.M.L., Martin-Liberal, J., Moreno, V., Trigo Perez, J.M., Le Tourneau, C., Mathew, M., Cho, D.C., Hansen, A.R., Vincente-Baz, D., Maio, M., Italiano, A., Bauman, J.R., Chisamore, M., Zhou, H., Ellis, C., Ballas, M., Hoos, A., Angevin, E.

Volltext

571 TLC388, a novel topoisomerase-1 inhibitor with anti-hypoxia inducible factor-1 alpha activity: a phase I and pharmacokinetic study in patients with advanced solid malignancies von Lin, C, Ghamande, S.A, Cho, D.C, Silverman, M.H, Fong, K, Kuo, M, Mach, W, Tseng, Y, Hsu, S.C, Goel, S

Volltext

Kim KT, Cho DC, Sung JK, Kim YB, Kang H, Song KS, Choi GJ von Kim, K.T, Cho, D.C, Sung, J.K, Kim, Y.B, Kang, H, Sonng, K.S, Choi, G.J

Volltext

Study on the TB and non-TB diagnosis using two-step deep learning-based binary classifier von Yoo, S. H., Geng, H., Chiu, T. L., Yu, S. K., Cho, D. C., Heo, J., Choi, M. S., Choi, I. H., Cung, C., Nhung, N., Min, B. J.

Volltext

Effect of powder mixing on thermoelectric properties in Bi2Te3-based sintered compounds von Lim, C.H., Kim, K.T., Kim, Y.H., Lee, Y.S., Lee, C.H., Cho, D.C.

Volltext

Thermoelectric properties of p-type Te doped Bi0.5Sb1.5Te3 fabricated by powder extrusion von PARK, K, SEO, J. H, CHO, D. C, CHOI, B. H, LEE, C. H

Volltext

Effect of powder mixing on thermoelectric properties in Bi 2Te 3-based sintered compounds von Lim, C.H., Kim, K.T., Kim, Y.H., Lee, Y.S., Lee, C.H., Cho, D.C.

Volltext

Thermoelectric properties of p-type Te doped Bi 0.5Sb 1.5Te 3 fabricated by powder extrusion von Park, K., Seo, J.H., Cho, D.C., Choi, B.H., Lee, C.H.

Volltext

Purification and Characterization of Monomeric Lysine Decarboxylase from Soybean (Glycine max) Axes von Kim, Hyo Sup, Kim, Byung Hyun, Cho, Young Dong

Volltext

Neuronal Hyperexcitability Mediates Below-Level Central Neuropathic Pain after Spinal Cord Injury in Rats von Park, E.S., Koatech Co., Pyeongtaek, Republic of Korea, Jeon, Y.H., Kyungpook National University, Daegu, Republic of Korea, Cho, D.C., Kyungpook National University Hospital, Daegu, Republic of Korea, Youn, D.H., Kyungpook National University, Daegu, Republic of Korea, Gwak, Y.S., University of Texas Medical Branch at Galveston, Galveston, USA

Volltext

TERRORISM CONCERNS RESTRICT TRANSPORT SYSTEM RESOURCES von Aileen Cho in Washington, D.C.

Volltext